Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYLYNK-012 in unresectable stage III non-small cell lung cancer
2023-503591-25-00Phase 3Authorised
- Sponsor
- Merck & Co.
- Start
- Nov 2023
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 26
01
Overview
Phase 3, randomised, double-blind trial of pembrolizumab, olaparib and durvalumab in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Merck & Co. Primary endpoints: Progression-Free Survival and Overall Survival. Planned start Nov 2023; status: authorised.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2023-503591-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503591-25-00.